Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70565 | 0.91 | AKR1B1 (0.71) | AKR1B1TSHRLMNAGAAKDM4E | |
| SCHEMBL7030142 | 0.90 | ACMSD (0.58) | AKR1B1TSHRLMNAGAAKDM4E | |
| SCHEMBL8405030 | 0.89 | CTBP2 (0.55) | AKR1B1LMNAKDM4ECYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL8922940 | 0.89 | AKR1B1 (0.68) | AKR1B1TSHRLMNAGAAKDM4E | |
| SCHEMBL4402323 | 0.84 | AKR1B1 (0.62) | AKR1B1TSHRLMNAGAAKDM4E | |
| SCHEMBL14704483 | 0.83 | AKR1B1 (0.56) | AKR1B1TSHRLMNAGAAKDM4E | |
| SCHEMBL5968748 | 0.83 | AKR1B1 (0.56) | AKR1B1TSHRLMNAGAAKDM4E | |
| Propionic Acid SCHEMBL5936395 | 0.83 | TSHR (0.48) | AKR1B1TSHRFFAR1ACMSDENPP2 | |
| SCHEMBL4557746 | 0.81 | AKR1B1 (0.64) | AKR1B1TSHRLMNAGAAKDM4E | |
| SCHEMBL21728869 | 0.81 | AKR1B1 (0.58) | AKR1B1TSHRLMNAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116675459-A | Preparation method of cementing material reinforcing agent with high compressive strength | 泉州市富霸新型材料科技发展有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-107903361-B | Preparation method of high-adaptability concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-12-29 | — | — | CN | claimed |
| CN-107955106-B | Preparation method of concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-12-29 | — | — | CN | claimed |
| CN-108047389-B | Preparation method of low-sensitivity concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-07-03 | — | — | CN | claimed |
| CN-108047388-B | Preparation method of shrinkage-reducing concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-07-03 | — | — | CN | claimed |
| CN-116675459-A | Preparation method of cementing material reinforcing agent with high compressive strength | 泉州市富霸新型材料科技发展有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-107955106-B | Preparation method of concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107903361-B | Preparation method of high-adaptability concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-108047389-B | Preparation method of low-sensitivity concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-108047388-B | Preparation method of shrinkage-reducing concrete fluidity stabilizer | 科之杰新材料集团有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-2991975-B1 | INHIBITORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, COMPOSITIONS, PRODUCTS AND USES THEREOF | UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO (IT) | 2017-07-19 | — | — | EP | disclosed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-08-02 | — | — | US | disclosed |
| EP-1646608-A4 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO LTD (KR) | 2006-11-22 | — | — | EP | disclosed |
| CN-1826316-A | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparation and pharmaceutical compositions containing them | JE IL PHARMACEUTICAL CO LTD (KR) | 2006-08-30 | — | — | CN | disclosed |
| EP-1646608-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL Pharmaceutical Co., Ltd. (KR) | 2006-04-19 | — | — | EP | disclosed |
| EP-1303512-B1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004113281-A1 | TRICYCLIC DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2004-12-29 | — | — | WO | disclosed |
| US-6372921-B1 | HALOGENATING ORTHO-XYLENE COMPOUND IN GAS PHASE OR LIQUID PHASE, REACTING PRODUCT WITH HYDROGEN CYANIDE OR SALTS THEREOF, REACTING WITH HALOGEN, HYDROLYZING IN WATER OR WATER CONTAINING PROTIC POLAR SOLVENT UNDER ACIDIC CONDITIONS | SHOWA DENKO K.K. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-1116720-A1 | PROCESSES FOR THE PREPARATION OF ISOCHROMANONES AND INTERMEDIATES FOR THE PREPARATION THEREOF | Showa Denko K.K. (JP) | 2001-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179143-A1 | Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | VEGFA, TUBB3, TUBA3C | AKR1B1 1355/4885TSHR 4522/4885LMNA 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.